for people ages 18 years and up (full criteria)
at Los Angeles, California and other locations
study started
completion around
Principal Investigator
by John Timmerman



This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Official Title

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy


CRG-022 is an autologous CAR T-cell therapy targeting CD22, a common B-cell antigen widely expressed in LBCL. This Phase 2 study is designed to evaluate the safety and the efficacy of CRG-022 in patients with R/R LBCL that has progressed after CD19-directed CAR T-cell therapy. The study is designed to treat up to 123 patients with a single infusion of CRG-022.


Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL), Lymphoma, CD-22 Expressing Tumor, Chimeric Antigen Receptor, Adoptive Immunotherapy, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Mediastinal B-cell, Lymphoma, Transformed, Lymphoma, Transformed Non-Hodgkin, Lymphoma, Non-Hodgkin, CAR T, CAR T-cell therapy, Cell Therapy, Cellular Immuno-therapy, CRG-022, CD22, B-Cell Lymphoma, Cyclophosphamide, Fludarabine, Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), CRG-022 cells (Experimental drug)


You can join if…

Open to people ages 18 years and up

  • Aged ≥18 years
  • Relapsed or refractory large B-cell lymphoma.
  • For enrollment in cohort 1, patients must have previously received a CD19-directed CAR T-cell therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematological, renal, and liver function

You CAN'T join if...

  • Clinically significant concurrent medical illness
  • Active infection requiring systemic antibiotics
  • Prior allogeneic stem cell transplant or allogeneic cell therapy

    Note: Other protocol defined Inclusion/Exclusion criteria may apply.


  • UCLA Division of Hematology Oncology accepting new patients
    Los Angeles California 90095 United States
  • City of Hope National Medical Center accepting new patients
    Duarte California 91010 United States

Lead Scientist at UCLA

  • John Timmerman
    Professor, Medicine. Authored (or co-authored) 71 research publications


accepting new patients
Start Date
Completion Date
CARGO Therapeutics
Sign up for this study
Phase 2 research study
Study Type
Expecting 123 study participants
Last Updated